

Resource Summary Report

Generated by NIF on Jul 28, 2026

Brilliant Violet 785(TM) anti-human CD14

RRID:AB_2561366

Type: Antibody

Proper Citation

BioLegend Cat# 301839, RRID:AB_2561366

Antibody Information

URL: http://antibodyregistry.org/AB_2561366

Proper Citation: BioLegend Cat# 301839, RRID:AB_2561366

Target Antigen: CD14

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 785(TM) anti-human CD14

Description: This monoclonal targets CD14

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone M5E2

Antibody ID: AB_2561366

Vendor: BioLegend

Catalog Number: 301839

Alternative Catalog Numbers: 301840

Record Creation Time: 20250819T234100+0000

Record Last Update: 20250820T060559+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 785(TM) anti-human CD14.

No alerts have been found for Brilliant Violet 785(TM) anti-human CD14.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Mattingly CLR, et al. (2025) Human lung CD8+ tissue-resident memory T cell-derived interferon- γ orchestrates subset-specific antiviral programming in airway epithelial cells. *Immunity*, 58(12), 3006.

Baiu DC, et al. (2025) CD8+ T cell antitumor immunity via human iNKT-DC conjugates. *Cancer immunology research*.

Lad M, et al. (2024) Glioblastoma induces the recruitment and differentiation of dendritic-like "hybrid" neutrophils from skull bone marrow. *Cancer cell*, 42(9), 1549.

Laforêts F, et al. (2023) Semi-supervised analysis of myeloid and T cell behavior in ex vivo ovarian tumor slices reveals changes in cell motility after treatments. *iScience*, 26(4), 106514.

Rwandamuriye FX, et al. (2023) A surgically optimized intraoperative poly(I:C)-releasing hydrogel prevents cancer recurrence. *Cell reports. Medicine*, 4(7), 101113.